Skip to Content
Search Results
Your search for 'guidelines' returned 209 results.

Document Downloads (32 items)

2014 Jun - APPGS meeting on Psoriasis Guidelines Implementation

2014 Jun - APPGS meeting on Psoriasis Guidelines Implementation

2015 Jan - Ipilimumab STA review - incorporation into melanoma guidelines

2015 Jan - Ipilimumab STA review - incorporation into melanoma guidelines

Actinic keratoses guidelines 2007

Actinic keratoses guidelines 2007

Alopecia areata guidelines 2003

Alopecia areata guidelines 2003

Azathioprine guidelines 2004

Azathioprine guidelines 2004

BAD National Audit 2012: Compliance with national guidelines

BAD National Audit 2012: Compliance with national guidelines

Basal cell carcinoma guidelines 1999

Basal cell carcinoma guidelines 1999

Bowen's disease guidelines 1999

Bowen's disease guidelines 1999

Bowen's disease guidelines 2007

Bowen's disease guidelines 2007

Bullous pemphigoid guidelines 2002

Bullous pemphigoid guidelines 2002

Contact dermatitis guidelines 2001

Contact dermatitis guidelines 2001

Contact dermatitis guidelines 2009

Contact dermatitis guidelines 2009

Cutaneous warts guidelines 2001

Cutaneous warts guidelines 2001

Lichen sclerosus guidelines 2002

Lichen sclerosus guidelines 2002

Lichen sclerosus guidelines 2018 Journal club slides

Lichen sclerosus guidelines 2018 Journal club slides

Melanoma guidelines 2002

Melanoma guidelines 2002

Melanoma guidelines 2007

Melanoma guidelines 2007

Melanoma guidelines 2010

Melanoma guidelines 2010

Methotrexate guidelines corrigendum - PIIINP unit

Methotrexate guidelines corrigendum - PIIINP unit

Occupational contact dermatitis guidelines 2011

Occupational contact dermatitis guidelines 2011

Onychomycosis guidelines 2003

Onychomycosis guidelines 2003

Pemphigus vulgaris guidelines 2003

Pemphigus vulgaris guidelines 2003

Photodynamic therapy guidelines 2002

Photodynamic therapy guidelines 2002

Photodynamic therapy guidelines 2002

Photodynamic therapy guidelines 2002

Photodynamic therapy guidelines 2008

Photodynamic therapy guidelines 2008

Primary cutaneous T-cell lymphomas guidelines 2003

Primary cutaneous T-cell lymphomas guidelines 2003

PUVA guidelines 1994

PUVA guidelines 1994

Squamous cell carcinoma guidelines 2002

Squamous cell carcinoma guidelines 2002

Squamous cell carcinoma guidelines 2009

Squamous cell carcinoma guidelines 2009

Tinea capitis guidelines 2000

Tinea capitis guidelines 2000

Topical PUVA guidelines 2000

Topical PUVA guidelines 2000

Urticaria and angio-oedema guidelines 2001

Urticaria and angio-oedema guidelines 2001

Event (6 items)

04/04/2019 - St John's Dermatological Society Meeting

St John's Dermatological Society Meeting St John's Dermatological Society Meeting Date: 4th April 2019 (3 CPD points, code121542) Venue:St John's Institute of Dermatology, Guys Hospital, Bermondsey Wing Organiser:Dr Andrew Pink Contact Name:Elena de Teran Contact Email: derm-courses@kcl.ac.uk Please wear your Trust ID badges to all meetings 4th April 2019 (3 CPD points, code 121542) - Guy's Hospital, London Bridge 3.15: Clinical cases: Outpatient Department, St. John's Institute,...

15/01/2015 - RSM Morning meeting “ Beyond Guidelines “

RSM Morning meeting “ Beyond Guidelines “ RSM Morning meeting " Beyond Guidelines " Case based discussions of managing dermatological conditions when standard advice has failed Date: 15th January2015 Venue: Royal Society of Medicine Organiser: Dermatology Academic Department Phone: +44 (0) 20 7290 3934 Email: RSMAcademic.AdministratorOne@rsm.ac.uk

27/02/2014 - Non-Melanoma Skin Cancer Update Meeting

Non-Melanoma Skin Cancer Update Meeting The BAD Skin Cancer Sub-Committee and the Clinical Services Department are delighted tio announce a one day Non-Melanoma Skin Cancer Update Meeting. The course is a full day, but has half day registration options. The Registration form is attached. For further details please contact Sophie at conference@bad.org.uk 08:45 - 09:25 R egistration 09:25 - 09:30 I ntroduction P rof Chris Bunker, BAD President

Non-Melanoma Skin Cancer Update Meeting

Non-Melanoma Skin Cancer Update Meeting The BAD Skin Cancer Sub-Committee and the Clinical Services Department are delighted tio announce a one day Non-Melanoma Skin Cancer Update Meeting. The course is a full day, but has half day registration options. The Registration form is attached. For further details please contact Sophie at conference@bad.org.uk 08:45 - 09:25 R egistration 09:25 - 09:30 I ntroduction P rof Chris Bunker, BAD President

RSM Morning meeting “ Beyond Guidelines “

RSM Morning meeting “ Beyond Guidelines “ RSM Morning meeting " Beyond Guidelines " Case based discussions of managing dermatological conditions when standard advice has failed Date: 15th January2015 Venue: Royal Society of Medicine Organiser: Dermatology Academic Department Phone: +44 (0) 20 7290 3934 Email: RSMAcademic.AdministratorOne@rsm.ac.uk

St John's Dermatological Society Meeting

St John's Dermatological Society Meeting St John's Dermatological Society Meeting Date: 4th April 2019 (3 CPD points, code121542) Venue:St John's Institute of Dermatology, Guys Hospital, Bermondsey Wing Organiser:Dr Andrew Pink Contact Name:Elena de Teran Contact Email: derm-courses@kcl.ac.uk Please wear your Trust ID badges to all meetings 4th April 2019 (3 CPD points, code 121542) - Guy's Hospital, London Bridge 3.15: Clinical cases: Outpatient Department, St. John's Institute,...

Information (40 items)

88th Annual Meeting of the British Association of Dermatologists

88th Annual Meeting of the British Association of Dermatologists The 88th Annual Meeting of the British Association of Dermatologists took place at Liverpool ACC 1st - 4th July 2008. Report by Jonathan Batchelor (Cambridge) The brand new ACC in 2008's European Capital of Culture provided a suitably impressive setting for the 88th BAD Annual Meeting this July. The venue was completed only a few months before the meeting and the glass-topped building by award-winning WiIkinson Eyre...

89th Annual Meeting of the British Association of Dermatologists

89th Annual Meeting of the British Association of Dermatologists The 89th Annual Meeting of the British Association of Dermatologists took place at Glasgow SECC 7th - 10th July 2009. Report by Sameh Zaghloul (Leeds) Dear all, I am pleased to welcome you to the first report on the BAD annual conference by a SAS doctor. SASs form one of the most important foundation brick layers of dermatology, and this year gave greater recognition to this group by beginning with a pre-conference session...

97th Annual Meeting of the British Association of Dermatologists

97th Annual Meeting of the British Association of Dermatologists The 97th Annual Meeting of the British Association of Dermatologists took place at the ACC Liverpool 4th - 6th July 2017. Report by Rajesh Goel (Northampton) It was July and the time for annual Bad meeting. I was all set to attend the meeting with tickets booked and bag packed. The venue was the cultural city of Liverpool. Liverpool has some great memories for me as this is the City where I started my dermatology career in...

98th Annual Meeting of the British Association of Dermatologists

98th Annual Meeting of the British Association of Dermatologists The 98th Annual Meeting of the British Association of Dermatologists took place at the EICC Edinburgh 3rd - 5th July 2018. Report by Krishna S. Mukkanna and Mabs M.U. Chowdhury (Cardiff) Congratulations to Tanya Bleiker and the whole Conference team who extended us a warm welcome to the 98th BAD Annual Meeting in Edinburgh 2-5 July 2018 in the introduction in the meeting programme. This was one of the most well attended...

BAD Constitution

BAD Constitution CONSTITUTION Title and Objects 1. The Association shall be called the British Association of Dermatologists. Its objects shall be to promote for the public benefit the knowledge, practice and teaching of Dermatology and in furtherance of the above object but not otherwise: (a) To stimulate and promote appropriate medical and scientific research and to publish the results of such research. (b) To collect, collate and publish

BAD Constitution

BAD Constitution CONSTITUTION Title and Objects 1. The Association shall be called the British Association of Dermatologists. Its objects shall be to promote for the public benefit the knowledge, practice and teaching of Dermatology and in furtherance of the above object but not otherwise: (a) To stimulate and promote appropriate medical and scientific research and to publish the results of such research. (b) To collect, collate and publish

BAD Executive Committee

BAD Executive Committee Please note that Executive Committee meetings are held on the third Thursday in January, April and October and in July during the BAD Annual Meeting. Dr Ruth Murphy President in the Chair (7/18-7/20) Dr Tanya Bleiker President Elect (7/19-7/20) Dr George Millington Academic Vice President (7/19-7/21) Dr Louise Fearfield Clinical Vice President (7/18-7/20) Dr

BADBIR

BADBIR The British Association of Dermatologists' Biologic Interventions Register (BADBIR) was set up by the BAD* to follow up all patients receiving biologic therapy for psoriasis in the UK and Eire. Its aim is to investigate the long-term safety for patients treated with biologic agents, compared with conventional systemic therapy. BAD guidelines strongly recommend that all psoriasis patients on biologic therapies should be registered with BADBIR, which also has strong support from NICE....

British Photodermatology Group Position Statements

British Photodermatology Group Position Statements Below you will find BPG's position statements onUltraviolet (UV) emissions and Compact Fluorescent Lights,Phototherapy for skin disease,Photodynamic Therapy, and Sunbeds. Ultraviolet (UV) emissions and Compact Fluorescent Lights Background Legislation in Europe and United States has led to the phasing out of incandescent light bulbs by 2012 and 2014, respectively. Similar legislation has been passed in several other countries. The...

British Photodermatology Group Position Statements on Sun Awareness and Safety

British Photodermatology Group Position Statements on Sun Awareness and Safety Below you will find the British Photodermatology Group's position statments on Skin Photo-Protection, Sun Protection in Schools and Vitamin D. British Photodermatology Group Position Statements Skin Photoprotection Background Excessive exposure to ultraviolet radiation (UVR), particularly from a young age, is the main cause of melanoma and non-melanoma skin cancer [1], and also skin ageing. Exposure...

Bullous pemphigoid

Bullous pemphigoid Interim report BAD bullous pemphigoid national audit 2018 - report (December 2018) Email invitation to all UK working members (this audit is now closed) This is a national clinical audit developed in collaboration with the British Society for Medical Dermatology. It is based on the audit standards derived from the British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012 and is open to all BAD members in the UK and those in their...

Career Advice

Career Advice The SAS Grade The new specialty doctor contract is available to secondary care doctors working in non-training grades who are not general practitioners, who do not hold Certificate of Completion of Specialist Training and who do not hold a consultant post. It replaces the old contracts for Staff Grades and Associate Specialists. Both these grades are now closed to new entrants. Non GP clinical assistants, hospital practitioners, Trust grade doctors and others in non-standard...

Clinical Audits

Clinical Audits The British Association of Dermatologists (BAD) has a national clinical audit programme in place following the development of its quantitative (auditable) standards based on recommended audit points derived from evidence-based clinical guidelines. At least one national audit will be carried out every year, with the aim of ascertaining the membership's adherence to national guidelines, as well as providing the opportunity for the membership to participate in national audits...

Clinical Standards

Clinical Standards The Clinical Standards Unit was set up to provide dedicated support to the work of the Therapy Guidelines and Health Informatics sub-committees. The unit deals with all matters pertaining to clinical guidelines, clinical audits, information for patients, health informatics and other related areas. Please forward any queries regarding: clinical guidelines to guidelines@bad.org.uk clinical audits and clinical standards/effectiveness to clinicalaudit@bad.org.uk ...

Diplomas and Courses for General Practitioners

Diplomas and Courses for General Practitioners Listed below are Diploma courses which are intended to provide structured education in dermatology. As such they will form a part of the portfolio of a general practitioner wishing to practice as a GPwER in dermatology. They are not, however, a substitute for the practical experience required by the DoH guidelines for this group of doctors Cardiff University Department of Dermatology Postgraduate Diploma in Practical Dermatology This is a...

Documentation for Dermatologists

Documentation for Dermatologists The following list contains documents which may be useful when considering service provision issues. The Lessons for the NHS - Commissioning a Dermatology Service- This report highlights the BAD experience in dealing with poor commissioning practice, and contains recommendations for clinically-led commissioning going forward - 2013 BAD Guidance for Dermatology Specialist Outreach Service Provision- 2012 BAD Guidance for Commissioning Dermatology Services...

Draft Guidelines

Draft Guidelines The draft guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people below is out for consultation and comments are invited from Members by Thursday 12th July 2018. The adult guideline was published in 2016. Comments should be sent to the Clinical Standards Unit, at guidelines@bad.org.uk

Draft Service Guidelines

Draft Service Guidelines The British Association of Dermatologists' Clinical Services Unit is responsible for developing guidance that is solely or mostly focused on the organisation and delivery of dermatology healthcare services (service guidance). These differ from clinical guidelines which mainly deal with the process of care and consider how interventions should be delivered and by whom. Service guidance attempts to link these issues with the broader remit of the health service - in...

Events

Events Conferenceand Event Services The Conference and Event Services Department of the British Association ofDermatologists isresponsible for the organisation ofthe majority of meetings, conferences and events held onbehalf of the Association. These meetings are of the highest standardand range from trainingdays held at BAD House to the Annual Meeting.

Executive Committee

Executive Committee Executive Committee 2019 - 2020 Dr Ruth Murphy President in The Chair (7/18-7/20) Dr Tanya Bleiker President Elect (7/19-7/20) Dr George Millington Academic Vice President (7/19-7/21) Dr Louise Fearfield Clinical Vice President (7/18-7/20) Dr Tony Bewley Honorary Treasurer (7/19-7/22) DrTabi Leslie Honorary Secretary (7/19-7/21) Dr Bryan McDonald Assistant Honorary Secretary (7/19-7-21) Dr John Ingram Editor BJD

FY and CMT/IMT Awards

FY and CMT/IMT Awards Poster Abstract Awards Foundation Year Doctors and Core Medical/Internal MedicineTrainees attending the DermSchool event are offered the opportunity to submit an abstract for consideration for the poster presentation within theDermSchool session of the BAD Annual Meeting. Authors of the best three posters will be awarded with £100 each. The abstract submission deadline will be confirmed nearer the time of the DermSchool Event. Please note that abstracts will only...

GPwER Dermatology and Skin Surgery

GPwER Dermatology and Skin Surgery The Royal College of General Practioners (RCGP) have published a framework for Dermatology and Skin Surgeryin collaboration with the British Association of Dermatologists(BAD) and the Primary Care Dermatology Society (PCDS) in the context of the College's new generic framework for GPwERs and the implementation of a new national accreditation process, which will be overseen by the RCGP with the support of dermatology specialist organisations. The...

Guidelines & Fees

Guidelines & Fees These guidelines contain the membership categories that were approved by the BAD AGM on 3rd July 2017 and supersede all previous versions. All new membership applications will be in one of the categories listed. These guidelines should be studied carefully by the applicant, their proposer and seconder before the application form is completed. BACKGROUND The BAD was formed in 1920 and is a professional body of international dermatologists and has a membership of over...

Healthcare Professionals

Healthcare Professionals This section is dedicated to providing dermatologists, healthcare professionals and medical students with an up-to-date resource of guidelines, regulations and education. Here you can access the most recent healthcare legislation, clinical guidelines, industry reviews, educational resources, research advice and speciaist group information, in addtion to the SAS database registration and BADBIR. Please navigate using the side menu on the left. Clinical Standards...

How to Join

How to Join The BAD has 10 categories of membership which are outlined below. For full details please read the Membership Guidelines before completing your form. For further queries please contact: admin@bad.org.uk To join online, please use this link. ORDINARY MEMBERSHIP Open to Consultants on the Specialist Register and SAS doctors who has been fully committed to secondary care dermatology for a period of at least four years TRAINEE MEMBERSHIP Trainee membership for all trainees...

Isotretinoin 2012

Isotretinoin 2012 Email invitation to all UK working members (this audit is now closed) Dear member, We would like you to take part in a national audit organised by the BAD. This audit is based on BAD clinical guidelines for treatment of acne with isotretinoin. It should take no longer than 10 minutes. Please collect the notes of the last THREE patients (including at least one male and one female) who have completed treatment with isotretinoin for acne vulgaris (must be within the last...

Isotretinoin 2013-4

Isotretinoin 2013-4 Reports Final report (Exton et al., Clinical and Experimental Dermatology 2017; 42: 381-9) Interim report: Compliance with isotretinoin national guidelines - where are we 2 years since the last audit? (December 2014) A national clinical re-audit by the British Association of Dermatologists (BAD) based on audit standards derived from BAD clinical guidelines on the safe introduction and continued use of isotretinoin in acne in the UK. Graphs and summaries (PowerPoint...

July 2014 - June 2016

July 2014 - June 2016 BAD President's

Medical Students

Medical Students Handbook for Medical Students and Junior Doctors (2014) The handbook is available as anelectronic copyor hard copy. Hard copies can be ordered free of charge by medical schools or other healthcare organisations based in the UK or Ireland. Please allow 2 weeks for delivery. To place an order, contact

Non-melanoma skin cancer excision 2014

Non-melanoma skin cancer excision 2014 Reports Final report (Keith et al., Clinical and Experimental Dermatology 2017; 42: 46-53) Interim report - BAD national audit on non-melanoma skin cancer excision 2014 (June 2015) Graphs and summaries (PowerPoint file) Email invitation to all UK working members (this audit is now closed) Dear member, This is the first official BAD national audit on non-melanoma skin cancer excision, designed and piloted jointly

Paediatric eczema

Paediatric eczema Report UK multicentre audit of the management of eczema in children - official publication (January 2018) Eczema proforma section A (Word) Eczema proforma section B (Word) Eczema proforma section A (PDF) Eczema proforma section B (PDF) Interim report BAD-BSPD paediatric eczema national audit 2015 - interim report (December 2015)

Postgraduate Awards

Postgraduate Awards Fellowships -sources of funding for research, education, or travel to overseas meetings. All BAD and Dowling Club awards are awarded by one committee after the Winter and Summer closing dates to ensure that the distribution of funds is as fair as possible. Postgraduate fellowships are open to BAD members only. (This does not apply to the Richard B. Stoughton Memorial Fellowship) Richard B. Stoughton Memorial

Psoriasis

Psoriasis The BAD has produced a number of documents from multiple workstreams over the years to assist members in the overall management of patients with psoriasis. Please find below a list of the materials that are currently available throughout the website. Patient Information Leaflets (PILs) Psoriasis - an overview

Psoriasis 2013

Psoriasis 2013 Interim report The assessment and management of patients with psoriasis - where are we? (September 2013) A national clinical audit by the British Association of Dermatologists based on NICE clinical guidelines and audit standards Graphs and summaries (PowerPoint file) Email invitation to all UK working members (this audit is now closed) Dear member, This is an important national audit, based on the audit standards derived from NICE clinical guidelines for the...

Psoriasis 2017

Psoriasis 2017 Interim report The assessment and management of patients with psoriasis - where are we since the last audit? (Interim report, July 2018) A national clinical re-audit by the British Association of Dermatologists based on NICE clinical guidelines and audit standards Email invitation to all UK working members (this audit is now closed) 1st February 2017 This is an important national clinical (re-)audit, based on the standards derived from NICE clinical guidelines for the...

Service Guidance and Standards

Service Guidance and Standards The British Association of Dermatologists' Clinical Services Unit is responsible for developing guidance that focuses on the organisation and delivery of dermatology healthcare services (Service Guidance). These underpin clinical guidelines, which deal mainly with the prescribing and medical management of patients with skin diseases. Service Guidance encompasses both the overarching clinical pathway for patients, and the service aspects required in the delivery...

Skin Cancer

Skin Cancer This section contains information about skin cancer, sunscreens, Sun Awareness, the literature you can order from us, and more: There are two main categories of skin cancer - melanoma and non-melanoma. Melanoma (also known as 'malignant melanoma') is less common than non-melanoma cancers, but is the most dangerous. Non-melanoma skin cancers are mainly comprised of 'Basal Cell Carcinoma' (BCC) and 'Squamous Cell Carcinoma' (SCC). BCC is the most common and the least dangerous....

Sub-committees

Sub-committees Therapy Guidelines Sub-committee The Therapy Guidelines sub-committee commissions clinical guidelines for publication in the British Journal of Dermatology, collaborates with and helps prepare official responses to external organisations, for e.g. NICE, the the NHS and Royal College of Physicians, on issues surrounding clinical guidelines and therapies. The committee also produces and commissions the BAD's Patient Information Leaflets (PILs) and provide assistance in the...

Vitamin D

Vitamin D Vitamin D and the Sun In a change to previous advice, SACN now recommends a Reference Nutrient Intake (RNI, meaning the intake that will be adequate to meet the needs of 97.5% of the population) of 10 g/d (400 IU/d) vitamin D, year-round, for all over-4's.The RNI for vitamin D refers to intakes from all dietary sources: natural food sources; fortified foods (including infant formula milk); and supplements.Exposure of skin to UVB radiation is affected by a number of factors such as...

Vitamin D Consensus 2009

Vitamin D Consensus 2009 BAD position statement 2009 On this page you will find some advice about the sun, skin cancer prevention and vitamin D. As well as some general advice, you can also read a summary of the evidence (click here) on which we base our advice. 2009: BAD position of vitamin D: In recent months there has been much debate about the pros and cons of sunshine for your health. We know that UV light from the sun and sunbeds can increase risk of skin cancer. However,...

News (36 items)

01/03/2018 - Leading UK medical and aesthetic associations launch register to protect public from rogue cosmetic practitioners

Leading UK medical and aesthetic associations launch register to protect public from rogue cosmetic practitioners London, U.K. 01 March 2018 - The Joint Council for Cosmetic Practitioners (JCCP) has launched a not-for-profit register for practitioners of non-surgical cosmetic treatments today. The procedures covered include the injection of botulinum toxin and fillers, chemical peels/skin rejuvenation, laser treatments and hair restoration surgery. The register is open for practitioners to...

03/05/2018 - Expert comment on the BATHE trial - the effectiveness of bath additives for child eczema

Expert comment on the BATHE trial - the effectiveness of bath additives for child eczema Response from BAD member Dr Carsten Flohr: This is an important and welcome study in terms of improving our understanding of effective treatments for eczema. Previously, guidelines advised the use of bath emollients for the treatment of children. These can now be amended to reflect this new evidence, saving time, effort, and money for patients, their families and for the NHS; resources that can be...

03/07/2012 - Can you screen for skin cancer?

Can you screen for skin cancer? Skin Cancer is the most frequent type of cancer in the UK, but of the 100,000+ cases only ten percent will be the most deadly kind - melanoma - and of those affected only around 2,000 will die. If detected early melanoma has a good prognosis and the British Association of Dermatologists has been working to educate the public on the importance of early detection for some years. In research due to be released at the British Association of Dermatologists' Annual...

04/06/2015 - BAD response to independent report confirming "unmitigated disaster" at Nottingham Hospitals

BAD response to independent report confirming "unmitigated disaster" at Nottingham Hospitals We welcome the report which we feel summarises the series of errors that led to the collapse of key dermatology services in Nottingham. We agree that all involved parties must now work together to improve patient care and to rebuild services in the region. However, it is also crucial that the failures outlined in the report are accepted and learnt from. The CCGs claim that the health of Nottingham's...

04/07/2016 - Acne patients in the UK are being over-exposed to oral antibiotics, despite antibiotic resistance concerns

Acne patients in the UK are being over-exposed to oral antibiotics, despite antibiotic resistance concerns Doctors at the British Association of Dermatologists' Annual Conference have warned that oral antibiotics, which are routinely prescribed for acne, are being used for durations that exceed recommendations, despite concerns about antibiotic resistance. Dr Alison Layton and the dermatology team at Harrogate and District NHS Foundation Trust, say that reliance on oral antibiotics beyond...

05/02/2015 - BAD response to draft NICE guidance on Sunlight Exposure: Benefits and Risks

BAD response to draft NICE guidance on Sunlight Exposure: Benefits and Risks Below you will find the BAD's response, and suggested ammendments, to NICE's draft guidance on Sunlight Exposure: Benefits and Risks Following this consultation stage, the BAD will have the opportunity to review the revised guidelines before publication. The draft guidance can be found here:http://www.nice.org.uk/guidance/indevelopment/gid-phg77/consultation National Institute for Health and Care Excellence ...

05/09/2011 - Statement by The British Association of Dermatologists on Cosmetic Injections (Intradermal Fillers)

Statement by The British Association of Dermatologists on Cosmetic Injections (Intradermal Fillers) The recent PIP breast implant furore has resulted in questions not just about the regulation of cosmetic surgical procedures but also about regulation of injectable intradermal fillers. Injection of intradermal fillers is one of the most popular cosmetic procedures in the UK with hundreds of thousands of procedures performed annually, compared to less than 10,000 breast augmentation procedures....

09/07/2013 - Self service phototherapy?

Self service phototherapy? New ways of delivering a well-tried treatment - two studies presented at the British Association of Dermatologists' Annual Meeting 8-11 July 2013, Liverpool A lot of time can be used up waiting at the hospital to have regular phototherapy sessions for skin disease. This is a treatment that is often used for common conditions such as psoriasis and eczema. Usually this treatment is given in hospital-based phototherapy units and because travel or regular attendance...

10/06/2019 - 34 per cent of eczema self-management apps contain information which is inconsistent with international guidelines

34 per cent of eczema self-management apps contain information which is inconsistent with international guidelines Peer Reviewed | Systematic Review | Apps Thirty-four per cent of eczema smartphone applications (apps) contain information which is inconsistent with international guidelines, particularly regarding treatments and the progression of the condition, according to a new study of 98 apps, published in the British Journal of Dermatology. Eczema is one of the most common skin...

10/12/2014 - BAD reaction to BMJ report on privatisation of the NHS

BAD reaction to BMJ report on privatisation of the NHS A statement from Dr. David Eedy, President of the BAD, in regards to the research released by Professor Oliver in the British Medical Journal regarding NHS contracts and management salaries:: The news today that a third of NHS contracts in England have been awarded to private sector providers since the service was reorganised in 2013 is a fact that dermatologists and their patients are all too aware of. In fact, some estimates put the...

14/07/2015 - Charities and medics call for parliamentary inquiry into NHS staffing crisis

Charities and medics call for parliamentary inquiry into NHS staffing crisis Thirteen national groups representing doctors, nurses and patients are calling for a government inquiry into the chronic lack of doctors working in dermatology, following responses to Freedom of Information data released today that highlight staff shortages and variations in waiting times. In a letter to Dr Sarah Wollaston MP, Chair of the House of Commons Health Select Committee, the organisations urge the...

17/10/2018 - Appointment of New Editor of Clinical and Experimental Dermatology

Appointment of New Editor of Clinical and Experimental Dermatology Clinical and Experimental Dermatology, the prominent UK dermatology journal owned by the British Association of Dermatologists, has today announced the appointment of Dr Alexa Shipman as Editor of the journal. Dr Shipman will take over from Dr George Millington in January 2019. Dr Shipman trained in Oxford, doing her foundation jobs in the Oxford deanery. She then went on to do her medical training in Stoke Mandeville,...

21/06/2011 - Minister and celebrites back campaign to raise awareness of skin cancer amongst well-being, hair and beauty professionals

Minister and celebrites back campaign to raise awareness of skin cancer amongst well-being, hair and beauty professionals Ministers and celebrities are backing a campaign launched today by the Melanoma Taskforce and British Association of Dermatologists (BAD) to help well-being, hair and beauty professionals spot the signs of skin cancer in their clients. Skin cancer kills more than 2,500 people in the UK every year and its most deadly form, malignant melanoma, is now the second most common...

21/09/2015 - Etin Skin Solution found to contain corticosteroid betamethasone

Etin Skin Solution found to contain corticosteroid betamethasone The Medicines and Healthcare products Regulatory Agency (MHRA) and the British Association of Dermatologists are today warning people not to purchase or use Etin Skin Solution, a lotion claiming to treat skin conditions and known to have been supplied from various Asian and African beauty shops. Etin Skin Solution was brought to the attention of MHRA by a consultant at Birmingham Children's Hospital who became concerned...

24/08/2011 - Prolonged breastfeeding does not protect against eczema, global study shows

Prolonged breastfeeding does not protect against eczema, global study shows The largest worldwide study on the association between breastfeeding, time of weaning and eczema in children has concluded that there is no clear evidence that exclusive breastfeeding for four months or longer protects against childhood eczema, according to research due to be published in the British Journal of Dermatology 24th August 2011. The researchers, based at King's College London, The University of...

25/10/2013 - World Psoriasis Day – the UK situation

World Psoriasis Day – the UK situation An audit conducted by the British Association of Dermatologists (BAD), looking at the way in which newly published NICE guidelines on assessment and management of psoriasis patients are being implemented across the UK, is being released to mark World Psoriasis Day on Tuesday (29th October 2013). On the whole the results were very positive. However, despite NICE prioritising holistic assessment of people with psoriasis, the audit revealed that...

26/08/2012 - Psychological Interventions benefit people with skin conditions report concludes

Psychological Interventions benefit people with skin conditions report concludes The symptoms of some of the most common skin diseases could be alleviated through psychological interventions, according to a study released today in the British Journal of Dermatology. While it is accepted that psychological interventions can help with the emotional impact that many skin diseases entail, this study reveals that such services can actually improve physical symptoms also. In a study, published in...

30/11/2012 - Development of contact allergy and allergic contact dermatitis is on the increase – in spite of preventive measures and increased awareness.

Development of contact allergy and allergic contact dermatitis is on the increase – in spite of preventive measures and increased awareness. In a study, published in the British Journal of Dermatology1, a team of researchers in Denmark2 looked at the incidence rate and persistence of contact allergy and allergic contact dermatitis in a group of 8th grade school children followed up 15 years later. The study showed that cases of allergic contact dermatitis to nickel had not only persisted...

34 per cent of eczema self-management apps contain information which is inconsistent with international guidelines

34 per cent of eczema self-management apps contain information which is inconsistent with international guidelines Peer Reviewed | Systematic Review | Apps Thirty-four per cent of eczema smartphone applications (apps) contain information which is inconsistent with international guidelines, particularly regarding treatments and the progression of the condition, according to a new study of 98 apps, published in the British Journal of Dermatology. Eczema is one of the most common skin...

Acne patients in the UK are being over-exposed to oral antibiotics, despite antibiotic resistance concerns

Acne patients in the UK are being over-exposed to oral antibiotics, despite antibiotic resistance concerns Doctors at the British Association of Dermatologists' Annual Conference have warned that oral antibiotics, which are routinely prescribed for acne, are being used for durations that exceed recommendations, despite concerns about antibiotic resistance. Dr Alison Layton and the dermatology team at Harrogate and District NHS Foundation Trust, say that reliance on oral antibiotics beyond...

Appointment of New Editor of Clinical and Experimental Dermatology

Appointment of New Editor of Clinical and Experimental Dermatology Clinical and Experimental Dermatology, the prominent UK dermatology journal owned by the British Association of Dermatologists, has today announced the appointment of Dr Alexa Shipman as Editor of the journal. Dr Shipman will take over from Dr George Millington in January 2019. Dr Shipman trained in Oxford, doing her foundation jobs in the Oxford deanery. She then went on to do her medical training in Stoke Mandeville,...

BAD reaction to BMJ report on privatisation of the NHS

BAD reaction to BMJ report on privatisation of the NHS A statement from Dr. David Eedy, President of the BAD, in regards to the research released by Professor Oliver in the British Medical Journal regarding NHS contracts and management salaries:: The news today that a third of NHS contracts in England have been awarded to private sector providers since the service was reorganised in 2013 is a fact that dermatologists and their patients are all too aware of. In fact, some estimates put the...

BAD response to draft NICE guidance on Sunlight Exposure: Benefits and Risks

BAD response to draft NICE guidance on Sunlight Exposure: Benefits and Risks Below you will find the BAD's response, and suggested ammendments, to NICE's draft guidance on Sunlight Exposure: Benefits and Risks Following this consultation stage, the BAD will have the opportunity to review the revised guidelines before publication. The draft guidance can be found here:http://www.nice.org.uk/guidance/indevelopment/gid-phg77/consultation National Institute for Health and Care Excellence ...

BAD response to independent report confirming "unmitigated disaster" at Nottingham Hospitals

BAD response to independent report confirming "unmitigated disaster" at Nottingham Hospitals We welcome the report which we feel summarises the series of errors that led to the collapse of key dermatology services in Nottingham. We agree that all involved parties must now work together to improve patient care and to rebuild services in the region. However, it is also crucial that the failures outlined in the report are accepted and learnt from. The CCGs claim that the health of Nottingham's...

Can you screen for skin cancer?

Can you screen for skin cancer? Skin Cancer is the most frequent type of cancer in the UK, but of the 100,000+ cases only ten percent will be the most deadly kind - melanoma - and of those affected only around 2,000 will die. If detected early melanoma has a good prognosis and the British Association of Dermatologists has been working to educate the public on the importance of early detection for some years. In research due to be released at the British Association of Dermatologists' Annual...

Charities and medics call for parliamentary inquiry into NHS staffing crisis

Charities and medics call for parliamentary inquiry into NHS staffing crisis Thirteen national groups representing doctors, nurses and patients are calling for a government inquiry into the chronic lack of doctors working in dermatology, following responses to Freedom of Information data released today that highlight staff shortages and variations in waiting times. In a letter to Dr Sarah Wollaston MP, Chair of the House of Commons Health Select Committee, the organisations urge the...

Development of contact allergy and allergic contact dermatitis is on the increase – in spite of preventive measures and increased awareness.

Development of contact allergy and allergic contact dermatitis is on the increase – in spite of preventive measures and increased awareness. In a study, published in the British Journal of Dermatology1, a team of researchers in Denmark2 looked at the incidence rate and persistence of contact allergy and allergic contact dermatitis in a group of 8th grade school children followed up 15 years later. The study showed that cases of allergic contact dermatitis to nickel had not only persisted...

Etin Skin Solution found to contain corticosteroid betamethasone

Etin Skin Solution found to contain corticosteroid betamethasone The Medicines and Healthcare products Regulatory Agency (MHRA) and the British Association of Dermatologists are today warning people not to purchase or use Etin Skin Solution, a lotion claiming to treat skin conditions and known to have been supplied from various Asian and African beauty shops. Etin Skin Solution was brought to the attention of MHRA by a consultant at Birmingham Children's Hospital who became concerned...

Expert comment on the BATHE trial - the effectiveness of bath additives for child eczema

Expert comment on the BATHE trial - the effectiveness of bath additives for child eczema Response from BAD member Dr Carsten Flohr: This is an important and welcome study in terms of improving our understanding of effective treatments for eczema. Previously, guidelines advised the use of bath emollients for the treatment of children. These can now be amended to reflect this new evidence, saving time, effort, and money for patients, their families and for the NHS; resources that can be...

Leading UK medical and aesthetic associations launch register to protect public from rogue cosmetic practitioners

Leading UK medical and aesthetic associations launch register to protect public from rogue cosmetic practitioners London, U.K. 01 March 2018 - The Joint Council for Cosmetic Practitioners (JCCP) has launched a not-for-profit register for practitioners of non-surgical cosmetic treatments today. The procedures covered include the injection of botulinum toxin and fillers, chemical peels/skin rejuvenation, laser treatments and hair restoration surgery. The register is open for practitioners to...

Minister and celebrites back campaign to raise awareness of skin cancer amongst well-being, hair and beauty professionals

Minister and celebrites back campaign to raise awareness of skin cancer amongst well-being, hair and beauty professionals Ministers and celebrities are backing a campaign launched today by the Melanoma Taskforce and British Association of Dermatologists (BAD) to help well-being, hair and beauty professionals spot the signs of skin cancer in their clients. Skin cancer kills more than 2,500 people in the UK every year and its most deadly form, malignant melanoma, is now the second most common...

Prolonged breastfeeding does not protect against eczema, global study shows

Prolonged breastfeeding does not protect against eczema, global study shows The largest worldwide study on the association between breastfeeding, time of weaning and eczema in children has concluded that there is no clear evidence that exclusive breastfeeding for four months or longer protects against childhood eczema, according to research due to be published in the British Journal of Dermatology 24th August 2011. The researchers, based at King's College London, The University of...

Psychological Interventions benefit people with skin conditions report concludes

Psychological Interventions benefit people with skin conditions report concludes The symptoms of some of the most common skin diseases could be alleviated through psychological interventions, according to a study released today in the British Journal of Dermatology. While it is accepted that psychological interventions can help with the emotional impact that many skin diseases entail, this study reveals that such services can actually improve physical symptoms also. In a study, published in...

Self service phototherapy?

Self service phototherapy? New ways of delivering a well-tried treatment - two studies presented at the British Association of Dermatologists' Annual Meeting 8-11 July 2013, Liverpool A lot of time can be used up waiting at the hospital to have regular phototherapy sessions for skin disease. This is a treatment that is often used for common conditions such as psoriasis and eczema. Usually this treatment is given in hospital-based phototherapy units and because travel or regular attendance...

Statement by The British Association of Dermatologists on Cosmetic Injections (Intradermal Fillers)

Statement by The British Association of Dermatologists on Cosmetic Injections (Intradermal Fillers) The recent PIP breast implant furore has resulted in questions not just about the regulation of cosmetic surgical procedures but also about regulation of injectable intradermal fillers. Injection of intradermal fillers is one of the most popular cosmetic procedures in the UK with hundreds of thousands of procedures performed annually, compared to less than 10,000 breast augmentation procedures....

World Psoriasis Day – the UK situation

World Psoriasis Day – the UK situation An audit conducted by the British Association of Dermatologists (BAD), looking at the way in which newly published NICE guidelines on assessment and management of psoriasis patients are being implemented across the UK, is being released to mark World Psoriasis Day on Tuesday (29th October 2013). On the whole the results were very positive. However, despite NICE prioritising holistic assessment of people with psoriasis, the audit revealed that...

Patient Resource (95 items)

Acitretin

Acitretin Acitretin is a type of drug called a retinoid. Retinoids are closely related to Vitamin A and work by slowing down cell growth in the skin. ACITRETIN What are the aims of this leaflet? This leaflet has been written to help you understand more about Acitretin. It advises what it is, how it works, how it is used to treat skin conditions and where you can find out more about this drug. What is Acitretin and how does it work? Acitretin is a type of drug called a retinoid....

Acitretin

Acitretin British Association of Dermatologists' guidelines on the efficacy and use of acitretin in dermatology Ormerod AD, Campalani E, Goodfield MJD. Br J Dermatol 2010; 162: 952-963. Available via doi:10.1111/j.1365-2133.2010.09755.x

Actinic keratoses

Actinic keratoses Guidelines for the management of actinic keratoses. de Berker D, McGregor JM, Hughes BR. Br J Dermatol 2007; 56: 222-230.

Actinic keratoses

Actinic keratoses British Association of Dermatologists' guidelines for care of patients with actinic keratosis 2017 D. de Berker, J.M. McGregor, M.F. Mohd Mustapa, L.S. Exton and B.R. Hughes. Br J Dermatol 2017, 176: 20-43 Available via doi:10.1111/bjd.15107

Actinic keratoses

Actinic keratoses Actinic keratoses are areas of sun-damaged skin found predominantly on sun-exposed parts of the body, particularly the forearms, backs of the hands, face, ears, bald scalp and the lower legs. They may also occur on the lips. The terms actinic and solar are from Greek and Latin, respectively, for 'sunlight-induced', and the term keratosis refers to thickened skin. Actinic keratoses may be unsightly, sometimes they can itch, but generally are harmless. There is a very small...

Alitretinoin

Alitretinoin Alitretinoin (brand name Toctino) belongs to a group of drugs called retinoids, which are closely related to vitamin A. It works by reducing skin cell turnover and also helps to reduce skin inflammation. ALITRETINOIN What are the aims of this leaflet? This leaflet has been written to help you understand more about alitretinoin. It tells you what it is, how it works, how it is used and where you can find out more about it. What is alitretinoin and how does it work? ...

Alopecia areata

Alopecia areata British Association of Dermatologists' guidelines for the management of alopecia areata 2012 Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. Br J Dermatol 2012; 166: 916-926. Available via doi:10.1111/j.1365-2133.2012.10955.x

Alopecia areata

Alopecia areata MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-9.

APPGS meeting on uptake of NICE Guidelines and Quality Standards for Psoriasis

APPGS meeting on uptake of NICE Guidelines and Quality Standards for Psoriasis

Archive Clinical Guidelines

Archive Clinical Guidelines The British Association of Dermatologists has been publishing evidence-based clinical guidelines since the 1990s. All guidelines listed on this page have been superseded by newer iterations which can be found on the main clinical guidelines page and are available via Wiley.

Azathioiprine

Azathioiprine British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. Br J Dermatol 2011; 165; 711-734. Available via doi:10.1111/j.1365-2133.2011.10575.x

Azathioprine

Azathioprine Azathioprine has been available since the 1960s. It was developed initially to stop rejection of transplanted organs, such as kidneys. It is now used to treat a wide range of illnesses. It works by suppressing the body's own defence system (the immune system), either by itself or in combination with other drugs. Azathioprine is not a steroid and is considered to be safer in the long-term than steroid tablets. AZATHIOPRINE What are the aims of this leaflet? This leaflet has...

Azathioprine

Azathioprine Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004; 151: 1123-32.

Basal Cell Carcinoma (BCC)

Basal Cell Carcinoma (BCC) Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999; 141: 415-23.

Basal cell carcinoma (BCC)

Basal cell carcinoma (BCC) Guidelines for the management of basal cell carcinoma Telfer NR, Colver GB, Morton CA. Br J Dermatol 2008; 159: 35-48. Available via doi:10.1111/j.1365-2133.2008.08666.x

BHD Foundation

BHD Foundation Aims The Birt-Hogg-Dub (BHD) Foundation aims to advance and promote research into medical and molecular genetics in order to better understand, diagnose, prevent, cure and relieve BHD syndrome and freely disseminate the results of such research to the public, as well as to advance education of the public in medical and molecular genetics. Awards Available The BHD Foundation awards two types of grants in pursuit of our aims: Research Grants The BHD Foundation encourages...

Biologic therapy for psoriasis

Biologic therapy for psoriasis British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 C.H. Smith, Z.K. Jabbar-Lopez, Z.Z. Yiu, T. Bale, A.D. Burden, L.C. Coates, M. Cruickshank, T. Hadoke, E. MacMahon, R. Murphy, C. Nelson-Piercy, C.M. Owen, R. Parslew, E. Peleva, E. Pottinger, E.J. Samarasekera, J. Stoddart, C. Strudwicke, V. A. Venning, R.B. Warren, L.S. Exton and M.F. Mohd Mustapa. Br J Dermatol 2017; 177: 628-136. Available via doi: 10.1111/bjd.15665 ...

Biologics

Biologics Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists'...

Bowen's disease (SCC in situ)

Bowen's disease (SCC in situ) Cox NH, Eedy DJ, Morton CA. Guidelies for management of Bowen's disease: 2006 update. Br J Dermatol 2007; 156: 11-21. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. Br J Dermatol 1999; 141: 633-41.

Bowen's disease (squamous cell carcinoma in situ)

Bowen's disease (squamous cell carcinoma in situ) Squamous cell carcinoma in situ, often called Bowen's disease, is a growth of cancerous cells that is confined to the outer layer of the skin. It is not a serious condition, and its importance rests on the fact that, very occasionally, it can progress into an invasive skin cancer known as squamous cell carcinoma (see Patient Information Leaflet on Squamous Cell Carcinoma for further information). For this reason, dermatologists usually treat,...

Brodalumab

Brodalumab Brodalumab is a biologic medicine that has been designed to treat psoriasis. It works by specifically targeting a chemical messenger (known as a 'cytokine') in the body called 'interleukin-17A' (IL-17A). We know that IL-17A is one of the main causes of inflammation in psoriasis, and by blocking it brodalumab can improve symptoms of psoriasis. BRODALUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about brodalumab...

Bullous pemphigoid

Bullous pemphigoid British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012 Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. Br J Dermatol 2012; 167: 1200-1214. Available via doi:10.1111/bjd.12072

Bullous pemphigoid

Bullous pemphigoid Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21.

Cellulitis and Erysipelas

Cellulitis and Erysipelas Erysipelas and cellulitis are common infections of the skin. Erysipelas is a superficial infection, affecting the upper layers of the skin, while cellulitis affects the deeper tissues. They can overlap, so it is not always possible to make a definite diagnosis between the two. CELLULITIS AND ERYSIPELAS What are the aims of this leaflet? This leaflet has been written to help you understand more about cellulitis and erysipelas. It tells you what these conditions...

Ciclosporin

Ciclosporin Like penicillin, ciclosporin is a substance produced by a fungus. Ciclosporin was found to suppress the immune system and was initially developed for suppressing the immune system of transplant patients to prevent them rejecting their transplanted kidneys and other organs. It was subsequently found to benefit patients with a wide range of diseases caused by immune reactions. CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand...

Ciclosporin

Ciclosporin British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018 Berth-Jones J, Exton LS, Ladoyanni E, Mohd Mustapa MF, Tebbs VM, Yesudian PD, Levell NJ. Br J Dermatol. 2019 Jun;180(6):1312-1338. Available via doi:10.1111/bjd.17587

Clinical Guidelines

Clinical Guidelines British Association of Dermatologists' clinical guidelines, as published in the British Journal of Dermatology: NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The accreditation recognises the stringent protocol that the BAD employs in producing clinical guidelines. The renewed accreditation is valid until 31st May 2021 and applies to guidance produced using the processes described in...

Contact dermatitis

Contact dermatitis British Association of Dermatologists' guidelines for the management of contact dermatitis 2017 G.A. Johnston, L.S. Exton, M.F. Mohd Mustapa, J.A. Slack, I.H. Coulson, J.S.C. English and J.F. Bourke JF. Br J Dermatol 2017; 176: 317-329. Available via doi:10.1111/bjd.15239 ECRI Trust Scorecard - requires registration (free) for access

Contact dermatitis

Contact dermatitis Bourke J, Coulson I, English J. Guidelines for care of contact dermatitis. Br J Dermatol 2009; 160: 946-954. Bourke J, Coulson I, English J. Guidelines for care of contact dermatitis. Br J Dermatol 2001; 145: 877-85.

Contact dermatitis

Contact dermatitis Dermatitis describes a type of inflammation of the skin. Dermatitis and eczema mean the same thing. Contact dermatitis describes inflammation that is caused by direct skin contact with something in your environment. It is sometimes called contact eczema. CONTACT DERMATITIS What are the aims of this leaflet? This leaflet has been written to help you understand more about contact dermatitis. It will tell you what it is, what causes it, what can be done about it, and...

Cutaneous T cell lymphoma

Cutaneous T cell lymphoma Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.Br J Dermatol 2003; 149: 1095-1107.

Cutaneous warts

Cutaneous warts Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol 2001; 144: 4-11.

Cutaneous warts

Cutaneous warts British Association of Dermatologists' guidelines for the management of cutaneous warts 2014 Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. Br J Dermatol 2014; 171; 696-712. Available via doi:10.1111/bjd.13310

Degos Disease Support Network

Degos Disease Support Network About us The Degos Disease Support Network is an information hub for patients diagnosed with this very rare disease. It offers

Dupilumab

Dupilumab Dupilumab is a biologic medicine that has been designed to treat eczema. It works by reducing inflammation. It works on chemical messengers (known as a 'cytokines') in the body called 'interleukin-4' (IL-4) and 'interleukin-13' (IL-13). DUPILUMAB FOR ATOPIC ECZEMA What are the aims of this leaflet? This leaflet has been written to help you understand more about dupilumab (Dupixent(r)). It tells you how it works, why you have been chosen for treatment, possible side-effects,...

ECCI response to Nuffield Council on Bioethics Cosmetic Procedures Call for Evidence

ECCI response to Nuffield Council on Bioethics Cosmetic Procedures Call for Evidence The Nuffield Council on Bioethics Cosmetic Procedures Call for Evidence, March 2016 Response from the Expert Council on Cosmetic Interventions (ECCI), formed from experts members of the British Association of Dermatologists (BAD), British Association of Aesthetic Plastic Surgeons (BAAPS), and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) Questions 9-15, The Supply and...

Generalised pruritus

Generalised pruritus British Association of Dermatologists' guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis 2018 G.W.M. Millington, A. Collins, C.R. Lovell, T.A. Leslie, A.S.W. Yong, J.D. Morgan, T. Ajithkumar, M.J. Andrews, S.M. Rushbook, R.R. Coelho, S.J. Catten, K.Y.C. Lee, A.M. Skellett, A.G. Affleck, L.S. Exton, M.F. Mohd Mustapa, N.J. Levell. Br J Dermatol 2018; 178: 34-60. Available via: doi:10.1111/bjd.16117

Guselkumab

Guselkumab Guselkumab is a biologic medicine that has been designed to treat psoriasis. It works by specifically targeting a chemical messenger (known as a 'cytokine') in the body called 'interleukin-23' (IL-23). We know that IL-23 is one of the main causes of inflammation in psoriasis, and by blocking it guselkumab can improve symptoms of psoriasis. Guselkumab What are the aims of this leaflet? This leaflet has been written to help you understand more about guselkumab (Tremfya(r)). It...

Hidradenitis suppurativa

Hidradenitis suppurativa British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, Desai N, Goodacre TEE, Piguet V, Pink AE, Exton LS, Mohd Mustapa MF. Br J Dermatol. 2019 May;180(5):1009-1017. Available via: doi: 10.1111/bjd.17537

How to care for your hands

How to care for your hands Our hands come into daily contact with many substances such as household detergents and cleaning products; personal cleansers including soaps, shampoos and wet wipes; food components such as fruit acids and plant chemicals and water.These can take away the protective oils that keep the skin moist, leading to chapping, dryness, and irritation.Frequent contact with water is one of the commonest causes of skin irritation.Once the skin on the hands is irritated and...

Hydroxychloroquine

Hydroxychloroquine Hydroxychloroquine is one of several antimalarial drugs that have anti-inflammatory effects useful in other diseases. Hydroxychloroquine is particularly effective for systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE). By reducing inflammation, hydroxychloroquine can decrease pain, swelling and stiffness of joints, and improve or clear some rashes. HYDROXYCHLOROQUINE What are the aims of this leaflet? This leaflet has been written to provide...

Immunisation recommendations for children and adult patients treated with immune-suppressing medicines

Immunisation recommendations for children and adult patients treated with immune-suppressing medicines This leaflet has been written to give you information aboutimmunisations (vaccinations), which may affect you when you are taking medicines that act by suppressing the immune system. This includes information about vaccinations which are: 1. Recommended before you start immune suppressing medicines 2. Safe for you to have while you are taking this treatment 3. Need to be avoided ...

Isotretinoin

Isotretinoin Isotretinoin (brand name Roaccutane) belongs to a group of drugs called retinoids, which are closely related to vitamin A. It works in a variety of ways, targeting different factors that cause acne including the production of sebum (an oily substance produced by the skin) and the production of keratin (outer scales of skin) that block the pores of the hair follicle. ISOTRETINOIN What are the aims of this leaflet? This leaflet has been written to help you understand more...

Ixekizumab

Ixekizumab Ixekizumab is a biologic medicine that has been designed to treat psoriasis. It works by specifically targeting a chemical messenger (known as a 'cytokine') in the body called 'interleukin-17A' (IL-17A). We know that IL-17A is one of the main causes of inflammation in psoriasis and psoriatic arthritis, and by blocking it ixekizumab can improve symptoms of these conditions. Ixekizumab What are the aims of this leaflet? This leaflet has been written to help you understand more...

Lichen sclerosus

Lichen sclerosus British Association of Dermatologists' guidelines for the management of lichen sclerosus 2018. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, Mohd Mustapa MF and Exton LS. Br J Dermatol 2018; 178: 839-853. Available via doi:10.1111/bjd.16241 ECRI Trust Scorecard - requires registration (free) for access

Lichen sclerosus

Lichen sclerosus Neill SM, Tatnall FM, Cox NH. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002; 147: 640-9

Lichen sclerosus (female)

Lichen sclerosus (female) Lichen sclerosus is a chronic inflammatory skin condition which can affect any part of the skin, but it most often affects the genital skin (vulva) and the skin around the anus. It can start in childhood - or adulthood (usually after the menopause) and affect girls or women of any age. LICHEN SCLEROSUS in Females What are the aims of this leaflet? This leaflet has been written to help you understand more about lichen sclerosus (LS). It tells you what it is,...

Lichen sclerosus (male)

Lichen sclerosus (male) Lichen sclerosus is a chronic inflammatory skin condition which can affect any part of the skin, but in men is most often seen on the foreskin and tip of the penis. It can affect boys or men of any age. In some people, lichen sclerosus also affects the skin elsewhere on the body, where it can cause whitish patches of skin, but usually no discomfort. MALE GENITAL (PENIS) LICHEN SCLEROSUS What are the aims of this leaflet? This

Melanoma

Melanoma Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C. Revised U.K guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238-256. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N. Guidelines for the management of cutaneous melanoma. Br J Dermatol 2002 146: 7-17.

Melanoma

Melanoma Revised U.K. guidelines for the management of cutaneous melanoma 2010. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, MacKie R, Nathan P, Peach H, Powell B, Walker C. Br J Dermatol 2010; 163: 238-256. "The British Association of Dermatologists decided not to update this guideline (see Archive Clinical Guidelines page) due to the publication of the National Institute for Health and Care Research (NICE) guideline Melanoma: assessment and...

Melanoma - Stage 1B

Melanoma - Stage 1B Melanoma is a type of skin cancer, which arises from the pigment cells (melanocytes) in the skin. One of the most important causes of melanoma is exposure to too much ultraviolet light in sunlight. The use of artificial sources of ultraviolet light, such as sunbeds, also increases the risk of getting a melanoma. Melanoma is considered to be the most serious type of skin cancer because it is more likely to spread (metastasise) from the skin to other parts of the body than...

Melanoma: Joint with Royal College of Physicians

Melanoma: Joint with Royal College of Physicians The prevention, diagnosis, referral and management of melanoma of the skin: conise guidelines Newton Bishop J, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, Ormerod A, Wheelhouse C, Royal College of Physicians, British Association of Dermatologists. Concise guidance to good practice series, no. 7. London: RCP, 2007. The chair of the melanoma guidelines group reviewed the guidelines in July 2012 and decided that no update was necessary

Mepacrine

Mepacrine Mepacrine was originally introduced as a treatment for malaria and for certain other tropical infections. It is an unlicensed medication in the United Kingdom. It is one of several antimalarial drugsthat have also been found to have anti-inflammatory properties, which can help some skin conditions. MEPACRINE What are the aims of this leaflet? This leaflet has been written to help you understand more about mepacrine. It tells you what it is, how it works, how it is used to...

Methotrexate

Methotrexate Methotrexate is known as a disease-modifying drug or DMARD. It slows the production of new cells by the body's immune system (the body's immune defence system) and reduces inflammation. It was first used to treat certain types of cancer and was discovered to be an effective treatment for skin and joint diseases when used at lower doses. METHOTREXATE What are the aims of this leaflet? This leaflet has been written to help you understand more about methotrexate. It tells you...

Methotrexate

Methotrexate British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016 Warren R.B., Weatherhead S.C., Smith C.H., Exton L.S., Mohd Mustapa M.F., Kirby B., Yesudian P.D. Br J Dermatol 2016; 175: 23-44. Available via doi:10.1111/bjd.14816

Mycophenolate mofetil

Mycophenolate mofetil Mycophenolate mofetil (MMF) is a medicine that is mainly used to stop the body from rejecting a transplanted organ (e.g. kidney, heart and liver). MMF can also be used to treat skin conditions. It reduces the action of the body's own defence system (the immune system) and is one of a group of drugs known as immunosuppressive agents. It is used in certain skin conditions in which the immune system loses control and begins to act against the body. MYCOPHENOLATE MOFETIL ...

NICE Draft Scope for Clinical Guidelines: Diagnosis and Management of Psoriasis in Young People and Adults

NICE Draft Scope for Clinical Guidelines: Diagnosis and Management of Psoriasis in Young People and Adults

NICE Draft Scope for Clinical Guidelines: Pressure Ulcers - prevention and management of pressure ulcers in primary and secondary care

NICE Draft Scope for Clinical Guidelines: Pressure Ulcers - prevention and management of pressure ulcers in primary and secondary care

NICE Guidelines Appraisal - pre-publication check: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

NICE Guidelines Appraisal - pre-publication check: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

NICE Guidelines Appraisal: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

NICE Guidelines Appraisal: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

NICE Guidelines Appraisal: Metastatic malignant disease of unknown primary origin

NICE Guidelines Appraisal: Metastatic malignant disease of unknown primary origin

NICE Ipilimumab STA review - incorporation into melanoma guidelines

NICE Ipilimumab STA review - incorporation into melanoma guidelines

Occupational contact dermatitis: Joint with Royal College of Physicians

Occupational contact dermatitis: Joint with Royal College of Physicians Diagnosis, management and prevention of occulational contact dermatitis: concise guidelines. Royal College of Physicians, British Association of Dermatologists, British Occupational Health Research Foundation, Faculty of Occupational Medicine, Health and Work Development Unit, NHS Plus. Concise guidance to good practice series, no 13. London: RCP, April 2011.

Omalizumab

Omalizumab Omalizumab is a drug that has been specially designed to mimic normal human molecules, and for this reason is classified as a biologic drug. It interferes with natural antibodies called IgEs in the body and prevents them from causing histamine release from certain cells. OMALIZUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about omalizumab. It tells you who it is for, how it works, how it is used to treat skin conditions and...

Onychomycosis

Onychomycosis British Association of Dermatologists' guidelines for the management of onychomycosis 2014 Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. Br J Dermatol 2014; 171: 937-58. Available via doi:10.1111/bjd.13358

Pemphigoid

Pemphigoid Pemphigoid is a rare blistering disorder, which usually occurs in later life, the average age of onset being over 70 years. The blisters come up on the skin and, less often, in the mouth too. This is in contrast to a related condition known as 'mucous membrane pemphigoid' in which the brunt of the trouble is borne by the moist surfaces of the body (the mucous membranes) such as the eyes, inside the nose and mouth, and the genitals. PEMPHIGOID What are the aims of this leaflet?...

Pemphigus vulgaris

Pemphigus vulgaris Guidelines for the management of pemphigus vulgaris. Harman KE, Albert S, Black MM. Br J Dermatol 2003; 149: 926-937.

Pemphigus vulgaris

Pemphigus vulgaris Pemphigus vulgarisis a rare autoimmune skin disease and affects around 3 people per 100,000 population. Pemphigus vulgaris may cause severe blistering of the skin and the mucous membranes lining the mouth, nose, throat, eyes and genital area. Blisters develop in the upper layer of the skin and have a thin and fragile outer surface that breaks away easily leaving raw areas (erosions) that can be extensive and painful. PEMPHIGUS VULGARIS What are the aims of this leaflet?...

Pemphigus vulgaris

Pemphigus vulgaris British Association of Dermatologists guidelines for the management of pemphigus vulgaris 2017 Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, Setterfield J, Yesudian PD. Br J Dermatol 2017; 177: 1170-1201. Available via doi: 10.1111/bjd.15930

Photodynamic therapy (PDT)

Photodynamic therapy (PDT) British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy (PDT) 2018 Wong TH, Morton CA,Collier N, Haylett A, Ibbotson S, McKenna KE, Mallipeedi R, Moseley H, Seukeran DC, Rhodes LE, Ward KE, Mohd Mustapa MF, Exton LS.. Br J Dermatol 2019; 180; 730-739. Available via doi:10.1111/bjd.17309

Photodynamic therapy (PDT)

Photodynamic therapy (PDT) Morton CA, McKenna KE, Rhodes LE on behalf of the British Association of Dermatologists Therapy Guideles and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-1266. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Mosele, H, Pearse AD, Stringer M, Taylor DK, Wong G, Rhodes, LE. Guidelines for topical photodynamic therapy: report of a...

Phototherapy

Phototherapy Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop. Taylor DK, Anstey AV, Coleman AJ, Diffey BL, Farr PM, Ferguson J, Ibbotson S, Langmack K, Lloyd JJ, McCann P, Martin CJ, du P. Menag H, Moseley H, Murphy G, Pye SD, Rhodes LE, Rogers S. Br J Dermatol 2002; 146: 755-763.

Phototherapy

Phototherapy Guidelines on the measurement of ultraviolet radiation levels in ultraviolet phototherapy: report issued by the British Association of Dermatologists and British Photodermatology Group 2015 Moseley H, Allan D, Amatiello H, Coleman A, du Peloux Menag H, Edwards C, Exton LS, Ferguson J, Garibaldinos T, Martin C, Mohd Mustapa MF. Br J Dermatol 2015; 173: 333-350. Available via doi:10.1111/bjd.13937

Pityriasis rubra pilaris

Pityriasis rubra pilaris Pityriasis rubra pilaris is a rare long-terminflammatory skin condition. The name means scaling (pityriasis), redness (rubra) and involvement of the hair follicles (pilaris). It affects all races and sexes equally. It is classified into 6 clinical types: Type I is the most common and is called 'classic adult type'. Type II is a variation of type I, known as atypical adult onset. Type III, IV and V represent classical, circumscribed and atypical juvenile...

Plantar warts

Plantar warts Warts are localised thickenings of the skin, and the term 'plantar warts'is used for those that occur on the soles of the feet (the 'plantar' surface). They are also known as verrucas. PLANTAR WARTS (VERRUCAS) What are the aims of this leaflet? This leaflet has been written to help you understand more about plantar warts. It tells you what they are, what causes them, what can be done about them, and where you can find out more about them. What are plantar warts? Warts...

Primary cutaneous lymphomas

Primary cutaneous lymphomas British Association of Dermatologists and U.K. Curaneous Lymphoma Group (CLG) guidelines for the management of primary cutaneous lymphomas 2018 Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, Mohd Mustapa MF, Exton LS, Kanfer E, Rezvani K, Dearden CE, Morris SL. Br J Dermatol 2019;180: 496-526. Available via doi: 10.1111/bjd.17240.

PUVA

PUVA British Association of Dermatologists' and British Photodermatology Group guidelines for the safe and effective use of PUVA therapy 2015. Ling TC, Clayton TH, Crawley J, Exton LS, Goulden V, Ibbotson S, McKenna K, Mohd Mustapa MF, Rhodes LE, Sarkany R, Dawe RS. Br J Dermatol 2016; 174: 24-55. Available via doi:10.1111/bjd.14317

PUVA

PUVA Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. Halpern SM, Anstey AV, Dawe RS, Diffey BL, Farr PM, Ferguson J, Hawk JLM, Ibbotson S, McGregor JM, Murphy GM, Thomas SE, Rhodes LE. Br J Dermatol 2000; 142: 22-31. British Photodermatology Group guidelines for PUVA. British Photodermatology Group. Br J Dermatol 1994; 130: 246-55.

Secukinumab

Secukinumab Secukinumab is a drug that has been specially designed to mimic normal human molecules, and for this reason it is classed as a 'biological' drug. It blocks the activity of a naturally occurring chemical 'cytokine' in the body called interleukin-17a (IL-17a). We know that psoriatic plaques contain high levels of IL-17a, and that it drives inflammation in the skin, leading to redness, thickening and flaking. SECUKINUMAB What are the aims of this leaflet? This leaflet has been...

Spironolactone

Spironolactone Spironolactone is a drug usually prescribed for patients with heart problems, high blood pressure and fluid retention. It can also have hormonal effects by blocking the action of androgens, "male hormones", that are normally produced by women in low levels. Some women have raised levels of androgens or increased sensitivity to normal levels of androgens and this can lead to skin disorders. Spironolactone thus can be used in the management of these conditions. Spironolactone ...

Squamous cell carcinoma (SCC)

Squamous cell carcinoma (SCC) Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 2002; 146; 18-25.

Squamous cell carcinoma (SCC)

Squamous cell carcinoma (SCC) Multi-professional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma 2009. Motley RJ, Preston PW, Lawrence CM -update of the original guideline which appeared in Br J Dermatol 2002; 146: 18-25.

Squamous cell carcinoma in situ (Bowen's disease)

Squamous cell carcinoma in situ (Bowen's disease) British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014 Morton CA, Birnie AJ, Eedy DJ. Br J Dermatol 2014; 170: 245-260. Available via doi:10.1111/bjd.12766

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 Creamer D, Walsh SA , Dziewulski P, Exton LS, Lee HY, Dart JKG, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KMT, Wong GAE, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH. Br J Dermatol 2016; 174: 1194-1227. This is a dual publication in the British Journal of...

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in children and young people

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in children and young people British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people 2018 McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, Tabor KL, Wali GN, Young AE, Mohd Mustapa MF, Murphy. R Br J Dermatol 2019; 181: 37-54. Available via doi 10.1111/bjd.17841

Thalidomide

Thalidomide Thalidomide was first introduced in 1957 as a sedative tablet that could also control severe morning sickness in pregnant women. When taken in pregnancy, it was associated with severe birth defects from which many babies died across the world. This did not result in any action for several years and it was withdrawn from the UK in 1961. After this tragedy, stronger rules were introduced to improve the safety of medicines. Thalidomide re-emerged as a therapeutic agent and in 1998...

Therapy & Guidelines

Therapy & Guidelines Therapy Guidelines Sub-Committee Function To commission clinical guidelines for the BAD, to collaborate with and help prepare official responses to external organisations on issues surrounding guidelines and therapies, to produce and commission the BAD's Patient Information Leaflets (PILs), to edit dermatology guidelines produced for GPs and to provide assistance in the updating of the British National Formulary. Part of the BAD's Clinical Standards Unit. Meetings...

Tinea capitis

Tinea capitis British Association of Dermatologists' guidelines for the management of tinea capitis 2014 Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM. Br J Dermatol 2014. 171: 454-63. Available via doi:10.1111/bjd.13196

Tinea capitis

Tinea capitis Higgins EM, Fuller LC, Smith CH. Guidelines for the management of tinea capitis. Br J Dermatol 2000; 143: 53-58

Tinea capitis

Tinea capitis Tinea capitis or 'scalp ringworm' is an infection of the scalp hair and the surrounding skin with a fungus. It is not cause by a worm, despite its name. It is called "ringworm" as it can cause a ring-shaped, scaly, red rash. Fungi are microscopic organisms that can live on the hair, nails, and outer skin layer. It occurs most commonly in children; however, it can also occur in adults. TINEA CAPITIS (or SCALP RINGWORM) What are the aims of this leaflet? This leaflet has...

Urticaria & angio-oedema

Urticaria & angio-oedema Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144: 708-14.

Urticaria (and Angioedema)

Urticaria (and Angioedema) Guidelines for evaluation and management of urticaria in adults and children Grattan CEH, Humphreys FY. Br J Dermatol 2007; 157: 1116-1123. Available via doi:10.1111/j.1365-2133.2007.08283.x

Ustekinumab

Ustekinumab Ustekinumab is a drug that has been specially designed to mimic normal human molecules, and for this reason it is classed as a 'biological' drug. It reduces skin inflammation by blocking the activity of chemical molecules called cytokines (interleukin 12 and 23) in the body that trigger inflammation in psoriasis. USTEKINUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about ustekinumab (StelaraTM). It tells you what it is, how...

Vitiligo

Vitiligo Guidelines for the management and diagnosis of vitiligo. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K. BrJ Dermatol 2008; 159; 1051-1076. Available via doi:10.1111/j.1365-2133.2008.08881.x

Vulvodynia

Vulvodynia Vulvodynia means ongoing pain in the vulva (the female genital area) when there is nothing abnormal to see and no known cause for the pain. Vestibulodynia is a term used for pain arising at the entrance of the vagina, in the area known as the vestibule (the area of the openings to the vagina and the urethra), when any pressure, be it touch or friction, is applied. It is also called localised vulvodynia. Vulvodynia, whether it is generalised or localised, may be described as...

Back to top